Back in early March 2020, the COVID-19 pandemic was still not much of a concern for the markets.
While investors were keeping an eye on it, compared to other geopolitical factors at the time, it was mostly an afterthought of little consequence.
Fast-forward a year and it seems we are still seeing the unraveling effects of the reality of COVID-19. Markets, health services, and politicians continue to struggle, as the pandemic spreads in scope and fear, with none the wiser as to whether the full impact will be relatively calm or worse than expected as new variants emerge.
But as new strains appear, so to do new plays; some are brand new companies, others have pivoted to capitalize on a variety of solutions the COVID problem has created.
Sponsored by 
Investors are shifting their correction investment strategies alongside market selloffs at large. A significant part of this strategy is to stay safe, calm, and diversified, but another key factor for many investors on the Stockhouse Bullboards is to gauge which companies will be able to recover, and when.
This week, we highlight two sides of the impact the markets have faced so far, by looking at the most-viewed companies in resources, as well as healthcare, specifically cannabis.
Starting with a look at what is happening in cannabis and the companies operating in and around that market,
Kalytera Therapeutics Inc. (TSX-V:KLY, Forum) is now going by the name
Claritas Pharmaceuticals, Inc. and this week, the CBD biotech company touted the potential of its proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection, citing new data by
Massachusetts General Hospital. Claritas has concentrated its
focus on the development on R-107. The nitric oxide-releasing compound. Following administration orally in a capsule, or by nasal spray, or by injection, R-107 enters the bloodstream, where it slowly releases nitric oxide systemically over 24 hours.